1. Home
  2. PUK vs BIIB Comparison

PUK vs BIIB Comparison

Compare PUK & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prudential Public Limited Company

PUK

Prudential Public Limited Company

HOLD

Current Price

$29.39

Market Cap

36.2B

Sector

Finance

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$200.14

Market Cap

29.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUK
BIIB
Founded
1848
1978
Country
Hong Kong
United States
Employees
15338
N/A
Industry
Life Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.2B
29.9B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PUK
BIIB
Price
$29.39
$200.14
Analyst Decision
Buy
Analyst Count
0
25
Target Price
N/A
$206.83
AVG Volume (30 Days)
775.7K
1.4M
Earning Date
03-26-2026
04-29-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.15
Revenue
N/A
$9,890,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$8.92
N/A
P/E Ratio
$23.76
$93.61
Revenue Growth
N/A
2.22
52 Week Low
$24.61
$124.56
52 Week High
$34.03
$219.72

Technical Indicators

Market Signals
Indicator
PUK
BIIB
Relative Strength Index (RSI) 59.68 49.99
Support Level $28.97 $186.24
Resistance Level $29.94 $202.91
Average True Range (ATR) 0.40 8.22
MACD 0.16 -0.67
Stochastic Oscillator 66.30 52.95

Price Performance

Historical Comparison
PUK
BIIB

About PUK Prudential Public Limited Company

Originally established in 1848 as the Prudential Mutual Assurance, Investment, and Loan Association, Prudential has changed a lot since. Set up to sell life insurance and loans to the middle class, the company subsequently diversified into Europe and then North America with the purchase of Jackson National Life around 1985. During its time as owner of Jackson, Prudential focused on building a simple chassis-style product portfolio that allowed customers to choose from a variety of add-ons. The company also became renowned for its focus on building the internal capabilities required to support its strong product offerings, including compelling technology and a large well-trained wholesale salesforce.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: